Number of shares and voting rights of Innate Pharma as at April 18, 2019
24 Avril 2019 - 7:00AM
Number of shares and voting rights of Innate Pharma as at April 18,
2019
NUMBER OF SHARES AND VOTING RIGHTS OF
INNATE PHARMA AS AT APRIL 18, 2019
Marseille,
France, April 24, 2018, 7:00 AM CET
Pursuant to the article L. 233-8 II of the
French « Code de Commerce » and the article 223-16 of the
French stock-market authorities (Autorité des Marchés Financiers,
or “AMF”) charter, Innate Pharma SA (the “Company” - Euronext
Paris: FR0010331421 – IPH) releases its total number of shares
outstanding as well as its voting rights as at April 18, 2019:
Total number of shares outstanding: |
64,043,905 “A” shares (ordinary shares) |
|
6,931 Preferred Shares 20167,581 Preferred Shares 2017 |
Total number of theoretical voting rights (1):Total number of
exercisable voting rights (2): |
64,051,48664,032,911 |
(1) The total number of theoretical voting
rights (or “gross” voting rights) is used as the basis for
calculating the crossing of shareholding thresholds. In accordance
with Article 223-11 of the AMF General Regulation, this number is
calculated on the basis of all shares to which voting rights are
attached, including shares whose voting rights have been
suspended.
(2) The total number of exercisable voting
rights (or ”net” voting rights) is calculated without taking into
account the shares held in treasury by the Company, with suspended
voting rights. It is released so as to ensure that the market is
adequately informed, in accordance with the recommendation made by
the AMF on July 17, 2007.
About Innate Pharma:
Innate Pharma S.A. is a fully integrated
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in
September 2018. Lumoxiti is a first-in class specialty oncology
product for hairy cell leukemia (HCL). Innate Pharma’s broad
pipeline of antibodies includes several first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and
development of checkpoint inhibitors, with a unique expertise and
understanding of Natural Killer cell biology. This innovative
approach has resulted in major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a landmark and multi-products partnership
with AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421IPH9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website www.amf-france.org or on Innate Pharma’s website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate
Pharma Dr. Markus Metzger / Danielle Spangler
/Jérôme Marino Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com |
International Media
Consilium Strategic Communications Mary-Jane
Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com |
|
French Media ATCG
Partners Solène Moulin Tel.: +33 (0)9 81 87 46 72
presse@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024